This is a preview of subscription content, log in via an institution to check access.
References
Alberti KGMM, Christensen SE, Iversen J, Juel Christensen N, Prange Hanson Aa, Lundbaek K, Seyer-Hansen K, Orskov H (1973) Inhibition of insulin secretion by somatostatin. Lancet II:1299–1301
Camisa C, O'Dorisio TM, Maceyko R, Schacht GE, Mekhjian HS, Howe BA (1989) Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin). I. An open-label pilot study. Cleve Clin J Med (in press)
Ghirlanda G, Uccioli L, Perri F, Altomonte L, Bertoli A, Manna R, Frati L, Greco AV (1983) Epidermal growth factor, somatostatin and psoriasis. Lancet I:65
Guilhou JJ, Boulanger A, Barneon G, Vic P, Meynadier J, Tardreu JC, Clot J (1982) Somatostatin treatment of psoriasis. Arch Dermatol Res 274:249–257
Kvols L, Moertel C, Rubin J, Reubi JC (1989) Somatostatin receptors (SR) may predict responsiveness of malignant neuroendocrine syndromes to therapy with somatostatin analogue (SMS 201-995, Sandostatin). Proc Am Soc Clin Oncol 8:101
Lamberts SWJ, Koper JW, Reubi JC (1987) Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 17:281–287
Nanney LB, Stoscheck M, Magid M, Kind LE Jr (1986) Altered (125J) epidermal growth factor binding and receptor distribution in psoriasis. Invest Dermatol 86:260–265
Nickoloff BJ, Misra P, Morhenn VB, Hintz RL, Rosenfeld RG (1987) Plasma somatomedin-C levels in psoriasis. Br J Pharmacol 116:15–20
Nickoloff BJ, Misra P, Morhenn VB, Hintz RL, Rosenfeld RG (1988) Further characterization of the keratinocyte somato-medin-C/insulin-like growth factor I (SM-C/IGF-I) receptor and the biological responsiveness of cultured keratinocytes to SM-C/IGF-I. Dermatologica 177:265–273
Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somato-statin receptor status. J Clin Endocrinol Metab 68:844–850
Reubi JC, HÄcki WH, Lamberts SWJ (1987) Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65:1127–1134
Reubi JC, Horisberger U, Lang W, Koper JW, Braakman P, Lamberts SWJ (1989) Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 134:337–344
Ritts RE, Kvols LK, Strehlo B, Jacobsen D, Patel S (1989) Immunologic studies of patients with malignant neuroendocrine carcinomas and responses to somatostatin analog (SMS 201-995, Sandostatin). Proc Am Assoc Cancer Res 30:281
Venier A, De Simone C, Forni L, Ghirlanda G, Uccioli L, Serri F, Frati L (1988) Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res 280 [Suppl]:S51-S54
Weber G, Klughardt G, Neidhardt M (1981) Psoriasis and human growth hormone: aetiology and therapy. Arch Dermatol Res 270:361–365
Weber G, Klughardt G, Neidhardt M, Galle K, Frey H, Geiger A (1982) Treatment of psoriasis with somatostatin. Arch Dermatol Res 272:31–36
Weber CJ, Jicha D, Matz S, Siverly J, O'Dorisio T, Strausberg L, Laurencot J, McCarty A, Norton J, Kazim M, Reemtsma K (1987) Passage of somatostatin analogue across human and mouse skin. Surgery 102:974–987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reubi, J.C., Hunziker, T. Absence of somatostatin receptors in psoriatic skin lesions. Arch Dermatol Res 282, 139–141 (1990). https://doi.org/10.1007/BF00493474
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00493474